Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Current Leases (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Current Leases for 6 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 25.54% to $2.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, up 25.54% year-over-year, with the annual reading at $2.8 million for FY2025, 25.54% up from the prior year.
  • Current Leases hit $2.8 million in Q4 2025 for Bolt Biotherapeutics, up from $2.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $3.0 million in Q2 2024 to a low of $1.6 million in Q1 2021.
  • Historically, Current Leases has averaged $2.5 million across 5 years, with a median of $2.5 million in 2021.
  • Biggest five-year swings in Current Leases: skyrocketed 66.62% in 2021 and later fell 19.09% in 2024.
  • Year by year, Current Leases stood at $2.5 million in 2021, then decreased by 4.4% to $2.4 million in 2022, then rose by 16.35% to $2.8 million in 2023, then fell by 19.09% to $2.3 million in 2024, then grew by 25.54% to $2.8 million in 2025.
  • Business Quant data shows Current Leases for BOLT at $2.8 million in Q4 2025, $2.7 million in Q3 2025, and $2.6 million in Q2 2025.